Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 29,083 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: dose level 1 Clear all

Conditions: Kidney Transplantation
Interventions: Mycophenolate mofetil, Cyclosporine, Tacrolimus; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years to 75 Years
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 57
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 48 more

Conditions: Keloid, Keloid Scar Following Surgery
Interventions: Triamcinolone Injection, Triamcinolone Injection and 5-fluorouracil injection; Drug
Lead sponsor: Our Lady of the Lake Hospital; Other
Eligibility: Not listed
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Hepatocellular Carcinoma
Interventions: BBI608, BBI503, Sorafenib; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 29
States / cities: Gilbert, Arizona • Phoenix, Arizona • Coronado, California + 25 more

Conditions: Advanced Solid Tumors
Interventions: ASP1570, pembrolizumab, Trifluridine + Tipiracil, Bevacizumab, Docetaxel, Oxaliplatin, Leucovorin, 5-Fluorouracil, Irinotecan, Pemetrexed, Carboplatin; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 12
States / cities: Fullerton, California • Los Angeles, California • Sarasota, Florida + 8 more

Conditions: Obesity
Interventions: Leuprolide, Testosterone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Community-acquired Infection
Interventions: GSK2251052 750 mg, GSK2251052 1500 mg, GSK2251052 1500 mg BID, GSK2251052 2250 mg, GSK2251052 3000 mg, GSK2251052 0.9% saline; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: Hypertension, Pulmonary, Lung Diseases, Interstitial
Interventions: TX000045; Drug
Lead sponsor: Tectonic Operating Company, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Phoenix, Arizona • San Francisco, California • Boise, Idaho + 1 more

Conditions: Prostate Cancer
Interventions: Leuprolide Acetate, Docetaxel, Bicalutamide, Radiation, Abiraterone Acetate; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Familial Platelet Disorder With Associated Myeloid Malignancy
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Questionnaire Administration, Sirolimus; Procedure · Other · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: 7-hydroxystaurosporine, cisplatin, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Cervical Cancer AJCC v6 and v7
Interventions: Bevacizumab, Cisplatin, External Beam Radiation Therapy, Internal Radiation Therapy; Biological · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 103
States / cities: Burbank, California • Sacramento, California • Colorado Springs, Colorado + 73 more

Conditions: Healthy
Interventions: ASC42, Placebo; Drug
Lead sponsor: Gannex Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Ulcerative Colitis Acute
Interventions: Cyclosporine Injection (IV), Cyclosporine Oral Product, Upadacitinib Extended Release Oral Tablet, Intravenous Methylprednisolone, Prednisone Oral Product; Drug
Lead sponsor: Berinstein, Jeffrey; Other
Eligibility: 18 Years to 75 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Solid Tumors
Interventions: TAK-593; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
Interventions: SB-509, Placebo; Biological · Other
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 19
States / cities: La Jolla, California • Lakewood, California • Lomita, California + 15 more

Conditions: Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7, Stage IB Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7
Interventions: Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Nab-paclitaxel, Paricalcitol, Pembrolizumab, Therapeutic Conventional Surgery; Drug · Other · Biological + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Juvenile Idiopathic Arthritis
Interventions: Rilonacept; Biological
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Months to 19 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Graft vs Host Disease
Interventions: Atorvastatin calcium; Drug
Lead sponsor: Mehdi Hamadani; Other
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 2
States / cities: Morgantown, West Virginia • Milwaukee, Wisconsin

Conditions: High-risk Diffuse Large B-cell Lymphoma
Interventions: Blinatumomab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Atlanta, Georgia • Maywood, Illinois • Cleveland, Ohio + 1 more

Conditions: Polycystic Ovary Syndrome
Interventions: 3-D Ultrasound, recombinant human chorionic gonadotropin, Recombinant human follicle stimulating hormone, Adrenocorticotropin, Dexamethasone, Glucose; Radiation · Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 37 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: San Diego, California

Conditions: HIV Infections
Interventions: Oral BMS-663068 (pro-drug); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Solid Tumors, Non-small Cell Lung Carcinoma
Interventions: DS-2248; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 9
States / cities: Duarte, California • Loma Linda, California • Orange, California + 6 more

Conditions: Pulmonary Hypertension
Interventions: VentaProst; Combination Product
Lead sponsor: Aerogen Pharma Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Stanford, California • Chicago, Illinois • Boston, Massachusetts

Conditions: Obesity
Interventions: AMG 598, Placebo, Liraglutide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Birmingham, Alabama • Tustin, California • South Miami, Florida + 1 more

Search by objective public record fields.

Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation

Post-Surgical Injection With Triamcinolone Versus Triamcinolone/Fluorouracil in Treatment of Keloids

A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Influence of Male Hormones on Regional Fat Metabolism

A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers

Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet Disorder

7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors

Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer

Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ASC42 in Healthy Subjects

Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis

Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery

Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults

Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation

Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome

A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)

A Study of DS-2248 in Participants With Advanced Solid Tumors

VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB

Multiple Ascending Dose Study of AMG 598 in Adults With Obesity